STOCK TITAN

Revolution Medicines Inc - RVMD STOCK NEWS

Welcome to our dedicated news page for Revolution Medicines (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revolution Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revolution Medicines's position in the market.

Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) announced financial results for Q4 and full year 2023, focusing on RAS(ON) inhibitors development. The company aims to advance RMC-6236 into pivotal trials for NSCLC and PDAC, expand its reach into earlier therapy lines and qualify mutant-selective inhibitors. With a year-end cash balance of $1.85 billion after acquiring EQRx, Revolution Medicines is well-positioned for future developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) will report financial results for Q4 and full year 2023 on Feb 26, 2024. The company is a clinical-stage oncology firm focusing on RAS-addicted cancers. A webcast by senior management will discuss financial results and corporate progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Revolution Medicines, Inc. CEO Mark A. Goldsmith, M.D., Ph.D. will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference. The company's participation details, including dates, times, and locations, are provided in the press release. Live webcasts and replays of the presentations will be available on the Revolution Medicines website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences
Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) announced that their CEO will deliver a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, to discuss the development of targeted therapies for RAS-addicted cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
-
Rhea-AI Summary
Revolution Medicines, Inc. (Nasdaq: RVMD) announced the completion of its acquisition of EQRx, Inc., adding approximately $1.1 billion in net cash to its balance sheet. This move supports the late-stage development of RAS(ON) Inhibitor investigational drugs. Dr. Sandra Horning, a seasoned oncologist and late-stage clinical development leader, has joined Revolution Medicines' Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.48%
Tags
acquisition
-
Rhea-AI Summary
RVMD and EQRX Stockholders Approve Acquisition Deal, Expected to Close in November 2023. Revolution Medicines to Issue 55 Million Shares for the Merger.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
acquisition
Rhea-AI Summary
Revolution Medicines, a clinical-stage oncology company, presented promising clinical data for RMC-6236 and RMC-6291 at AACR-NCI-EORTC and ESMO Meetings. The company also provided an update on its financial results and announced the expected close of the acquisition of EQRx, Inc. The clinical data showed significant anti-tumor activity for both drugs, supporting their advancement into late-stage development. The acquisition is expected to add approximately $1.1 billion in net cash proceeds. Revolution Medicines aims to revolutionize treatment for RAS-addicted cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
earnings
-
Rhea-AI Summary
Revolution Medicines, Inc. will report financial results for the third quarter 2023 on November 6, 2023, after market close. The senior management team will host a webcast to discuss the financial results and provide an update on corporate progress. A replay will be available on the company's website for at least 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
conferences earnings
-
Rhea-AI Summary
Revolution Medicines announces promising anti-tumor and safety data for RMC-6236 in patients with lung cancer and pancreatic cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Rhea-AI Summary
Revolution Medicines announces encouraging preliminary clinical data for RMC-6236 and RMC-6291
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.6%
Tags
clinical trial
Revolution Medicines Inc

Nasdaq:RVMD

RVMD Rankings

RVMD Stock Data

4.98B
106.98M
2.29%
96.47%
10.35%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About RVMD

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.